Microbicide Trials Network

MTN-003 - VOICE

Vaginal and Oral Interventions to Control the Epidemic – tested the safety and effectiveness of two different HIV prevention approaches among 5,029 women in Uganda, South Africa and Zimbabwe: daily use of an antiretroviral (ARV) tablet (tenofovir or Truvada) or daily use of a vaginal gel (tenofovir gel). The first set of results, reported in March 2013, found none of the products effective; most participants did not use them daily as recommended. Young, unmarried women were least likely to use study product and the most likely to acquire HIV, indicating the urgent need for safe, effective and practical HIV prevention methods women like those in VOICE will actually use. Results of two qualitative behavioral sub-studies, VOICE C and VOICE D, should help to better understand the reasons why so many women did not use the products in VOICE.

 

VOICE also included three sub-studies: VOICE B (Bone Mineral Density), VOICE C (Household and Community Factors Associated with Adherence), and VOICE D, which is looking to better understand women’s actual use of study products and sexual behavior during their participation in VOICE, and in particular to understand why women enrolled and remained in VOICE yet so few adhered to product use. While VOICE B and C have been completed, results are not yet available. VOICE D is ongoing with results expected in 2015.

 

Results

New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women

28-October-2014

  

Secondary Analysis of VOICE: Injectable Contraception and HIV Risk Q&A

31-March-2014

  

First Comparison Between Injectable Contraceptives DMPA and NET-EN Suggests Some Women Using DMPA Were at Higher Risk of Acquiring HIV

4-March-2014

  

Behavioral Measures of Product Use Didn’t Measure Up in VOICE HIV Prevention Trial, Report the Study’s Researchers

4-March-2014

  

Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

4-March-2013

  

Fact sheet – The VOICE C and VOICE D Social and Behavioral Research Sub-studies: Looking for answers about adherence and the women in VOICE     

4-September-2013

      

VOICE Fact Sheet – Understanding the Results of VOICE

4-March-2013

  

VOICE Q&A

4-March-2013      

  

NIAID Press Release on VOICE Results

4-March-2013

 

Other Study Milestones

Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women

25-November-2011

  

Questions and Answers on Decision to Modify VOICE, Outcome of November 17 DSMB Review

25-November-2011

             

Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women

28-September-2011

  

Questions and Answers on Decision to Modify VOICE, Outcome of September 16 DSMB Review

28-September-2011  

  

HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,000 Women

6-June-2011

  

VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe

16-September-2009

 

NIAID Press Release on start of VOICE

16-September-2009

  

HIV prevention trial of ARV-based strategies to begin next month

20-July-2009

 

VOICE and Related Trials

Questions and Answers about the CDC TDF2 Study and VOICE

14-July-2011

     

VOICE Study will Continue as it Considers What Action to Take After Results of Two Trials

13-July-2011

     

Questions and Answers about Partners PrEP and VOICE

13-July-2011

  

Microbicide Trials Network Statement on the status of VOICE Study following announcement to close the FEM-PrEP trial

18-April-2011

     

Trial shows ARVs can prevent HIV in men who have sex with men, making VOICE Study in women more important than ever

23-November-2010

     

Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE

19-July-2010

 

Understanding Resistance

Please note that the information contained in the following materials may have changed since publication.

Drug Resistance and ARV-Based Prevention Fact Sheet

  

Drug Resistance and ARV-Based Prevention Q&A

 

Diagrams:

 

Video: Drug Resistance and ARV-Based Prevention

  

See Also 

MTN-003 (VOICE) Study Protocol

 

MTN-003 B (VOICE B) Study Protocol

        

MTN-003 C (VOICE C) Study Protocol

       

MTN-003 D (VOICE D) Study Protocol